<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39324928</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2737-5935</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Singapore medical journal</Title><ISOAbbreviation>Singapore Med J</ISOAbbreviation></Journal><ArticleTitle>Anaphylaxis post-COVID-19 vaccinations in Singapore.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4103/singaporemedj.SMJ-2023-258</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Anaphylaxis was the first serious adverse event (AE) of special interest surfaced in Singapore following coronavirus disease 2019 (COVID-19) vaccination. Individuals who developed physician-diagnosed severe allergic reactions to the mRNA vaccines would be medically ineligible for mRNA vaccines and offered non-mRNA alternatives. This paper describes anaphylaxis reports received by the Health Sciences Authority (HSA) and presents a review of individuals who received heterologous COVID-19 vaccination.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Reports of anaphylaxis associated with the COVID-19 vaccines received till 31 July 2022 were reviewed and adjudicated using the Brighton Collaboration case definition criteria by an HSA-appointed expert panel. Additional review was conducted for cases with heterologous vaccination for any subsequent reactions until administration of third dose of COVID-19 vaccines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 112 adjudicated anaphylaxis cases, majority occurred in females, adults and persons with allergy histories, which were consistent with global observations. Most cases (71%) occurred within 30 minutes of vaccination. The reporting incidence rates (IRs) of 0.67 and 0.55 per 100,000 administered doses for Comirnaty and Spikevax vaccines, respectively, were comparable with IRs reported overseas, whereas the IRs for non-mRNA vaccines (Sinovac-CoronaVac and Nuvaxovid) were much higher at 4.14 and 29.82 per 100,000 administered doses, respectively, likely due to selection bias. Review of the 20 cases following heterologous vaccination found varying reactions to subsequent vaccinations.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Anaphylaxis is a rare but serious AE in which outcomes can be mitigated with timely medical intervention. The case review helped to guide vaccination strategies and added to the cumulative knowledge of safety with heterologous vaccination.</AbstractText><CopyrightInformation>Copyright © 2024 Copyright: © 2024 Singapore Medical Journal.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peck</LastName><ForeName>Li Fung</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Vigilance and Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poh</LastName><ForeName>Wang Woon</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Vigilance and Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Adena Theen</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Vigilance and Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soh</LastName><ForeName>Sally Bee Leng</ForeName><Initials>SBL</Initials><AffiliationInfo><Affiliation>Vigilance and Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tham</LastName><ForeName>Mun Yee</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Vigilance and Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foo</LastName><ForeName>Belinda Pei Qin</ForeName><Initials>BPQ</Initials><AffiliationInfo><Affiliation>Vigilance and Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Amelia Jing Jing</ForeName><Initials>AJJ</Initials><AffiliationInfo><Affiliation>Vigilance and Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Patricia Suet Ling</ForeName><Initials>PSL</Initials><AffiliationInfo><Affiliation>Vigilance and Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ang</LastName><ForeName>Pei San</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Vigilance and Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Cheng Leng</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toh</LastName><ForeName>Dorothy Su Lin</ForeName><Initials>DSL</Initials><AffiliationInfo><Affiliation>Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edmund Jon Deoon</ForeName><Initials>EJD</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santosa</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, National University Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thong</LastName><ForeName>Bernard Yu-Hor</ForeName><Initials>BY</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bever</LastName><ForeName>Hugo Van</ForeName><Initials>HV</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Immunology and Allergy, Department of Paediatrics, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Haur Yueh</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Singapore General Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sum</LastName><ForeName>Chee Fang</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Admiralty Medical Centre and Khoo Teck Puat Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorajoo</LastName><ForeName>Sreemanee Raaj</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Vigilance and Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teo</LastName><ForeName>Desmond Chun Hwee</ForeName><Initials>DCH</Initials><AffiliationInfo><Affiliation>Vigilance and Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Singapore Med J</MedlineTA><NlmUniqueID>0404516</NlmUniqueID><ISSNLinking>0037-5675</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39324928</ArticleId><ArticleId IdType="doi">10.4103/singaporemedj.SMJ-2023-258</ArticleId><ArticleId IdType="pii">00077293-990000000-00155</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The Health Sciences Authority, Singapore. Pandemic Special Access Route (PSAR) for Supply of Emergency Therapeutic Products. Available from: https://www.hsa.gov.sg/therapeutic-products/register/specialaccess-routes/psar-emergency-therapeutic-product. [Last accessed on 2022 Aug 23].</Citation></Reference><Reference><Citation>World Health Organisation. The use of the WHO-UMC system for standardized case causality assessment. Available from: https://www.who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf. [Last accessed on 2022 Nov 04].</Citation></Reference><Reference><Citation>Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5675–84.</Citation></Reference><Reference><Citation>Kohl KS, Bonhoeffer J, Braun MM, Chen RT, Duclos P, Heijbel H, et al. The Brighton Collaboration: Creating a global standard for case definitions (and guidelines) for adverse events following immunization Henriksen K, Battles JB, Marks ES, Lewin DI. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005.</Citation></Reference><Reference><Citation>Ministry of Health, Singapore. FAQ – COVID-19 vaccination. Available from: https://www.moh.gov.sg/covid-19/vaccination. [Last accessed 2022 Nov 04].</Citation></Reference><Reference><Citation>Leong P, Al-Harrasi M, Carr B, Leahy E, Bardin PG, Barnes S. Vocal cord dysfunction/inducible laryngeal obstruction(s) mimicking anaphylaxis during SARS-CoV-2 (coronavirus) vaccination. J Allergy Clin Immunol Pract 2022;10:1380–1.</Citation></Reference><Reference><Citation>Dreskin SC, Halsey NA, Kelso JM, Wood RA, Hummell DS, Edwards KM, et al. International Consensus (ICON): Allergic reactions to vaccines. World Allergy Organ J 2016;9:32.</Citation></Reference><Reference><Citation>Risma KA, Edwards KM, Hummell DS, Little FF, Norton AE, Stallings A, et al. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J Allergy Clin Immunol 2021;147:2075–82.e2.</Citation></Reference><Reference><Citation>Lim XR, Leung BP, Ng CYL, Tan JWL, Chan GYL, Loh CM, et al. Pseudo-anaphylactic reactions to Pfizer BNT162b2 vaccine: Report of 3 cases of anaphylaxis post Pfizer BNT162b2 vaccination. Vaccines (Basel) 2021;9:974.</Citation></Reference><Reference><Citation>Ko HL, Zhuo N, Chang ZW, Santosa A, Kalimuddin S, Lim XR, et al. In vitro vaccine challenge of PBMCs from BNT162b2 anaphylaxis patients reveals HSP90a-NOD2-NLRP3 nexus. Allergy 2022. doi: 10.1111/all.15503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15503</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian S, Li L, Wang Z, Cui L, Xu Y, Guan K, et al. Allergic reactions after the administration of COVID-19 vaccines. Front Public Health 2022;10:878081. doi: 10.3389/fpubh.2022.878081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.878081</ArticleId></ArticleIdList></Reference><Reference><Citation>Luxi N, Giovanazzi A, Arcolaci A, Bonadonna P, Crivellaro MA, Cutroneo PM, et al. Allergic reactions to COVID-19 vaccines: Risk factors, frequency, mechanisms and management. BioDrugs 2022;36:443–58.</Citation></Reference><Reference><Citation>Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 2021;326:1390–9.</Citation></Reference><Reference><Citation>Hwang I, Park K, Kim TE, Kwon Y, Lee YK. COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021. Osong Public Health Res Perspect 2021;12:396–402.</Citation></Reference><Reference><Citation>Wong CKH, Lau KTK, Xiong X, Au ICH, Lai FTT, Wan EYF, et al. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study. PLoS Med 2022;19:e1004018.</Citation></Reference><Reference><Citation>Chu DK, Abrams EM, Golden DBK, Blumenthal KG, Wolfson AR, Stone CA Jr, et al. Risk of second allergic reaction to SARS-CoV-2 vaccines: A systematic review and meta-analysis. JAMA Intern Med 2022;182:376–85.</Citation></Reference><Reference><Citation>Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med 2022;386:1046–57.</Citation></Reference><Reference><Citation>Ministry of Health, Singapore. FAQs on general vaccine recommendations. Available from: https://www.moh.gov.sg/covid-19/vaccination/faqs-on-general-vaccine-recommendations. [Last accessed on 2022 Nov 17].</Citation></Reference><Reference><Citation>Gold MS, Amarasinghe A, Greenhawt M, Kelso JM, Kochhar S, Yu-Hor Thong B, et al. Anaphylaxis: Revision of the Brighton collaboration case definition. Vaccine 2022:S0264-410X(22)01425-6.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>